3 hours ago
1
Natco Pharma reported consolidated nett net for the March 4th declined astir 34% to ₹269 crore compared with the ₹406 crore a twelvemonth earlier connected the backmost of a crisp autumn successful gross from formulations export.
Net gross declined much than 36% to ₹816.9 crore (₹1,287.3 crore). Shares of the generic drugmaker connected Friday closed 13.51% little connected the BSE astatine ₹1,016.75 apiece.
Barring formulations export which dropped to ₹539.6 crore (₹1,052.5 crore), the publication of different segments -- progressive pharmaceutical ingredients (APIs), home formulations, harvest wellness sciences arsenic good arsenic different operating and non-operating income -- was higher yoy.
For FY26, the company’s nett net declined astir 25% to ₹1,418.5 crore (₹1,883.4 crore) connected a full gross of ₹4,375.9 crore (₹4,784 crore). Besides formulations export, different operating and non-operating gross conception gross was besides little during the fiscal.
Net nett for the 4th and fiscal twelvemonth includes one-time payment of ₹115 crore arsenic the institution has elected to determination to the caller taxation authorities from 2026-27 and has re-measured its deferred taxation assets connected MAT recognition and different deferred taxation assets/liabilities.
During the 4th and the fiscal, an impairment nonaccomplishment of ₹50 crore was recognised connected the property, works and instrumentality of agro chemic segment, Natco Pharma said.
